What does SOBEN Pharma Robeerst do?

SOBEN Pharma Robeerst is a pharmacy in Esneux. Private Limited, started on 20 September 1976, 1 establishment.

What is the address of SOBEN Pharma Robeerst?

The registered office of SOBEN Pharma Robeerst is located at Rue de Bruxelles 17, 4130 Esneux.

Is SOBEN Pharma Robeerst still active?

Yes. According to the CBE (30 October 2026) SOBEN Pharma Robeerst is active, legal situation “Normale toestand”, started on 20 September 1976.

Is SOBEN Pharma Robeerst registered on Peppol?

Yes, SOBEN Pharma Robeerst is registered on the Peppol network with ID 0208:0416405162.

What is the enterprise number of SOBEN Pharma Robeerst?

The enterprise number of SOBEN Pharma Robeerst is BE0416405162.

When was SOBEN Pharma Robeerst founded?

SOBEN Pharma Robeerst was founded on 20 September 1976.

Who are the directors of SOBEN Pharma Robeerst?

According to the 2025 annual accounts, the directors of SOBEN Pharma Robeerst are: Alphar Esneux SA.

Is SOBEN Pharma Robeerst a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 September 1976; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SOBEN Pharma Robeerst make in 2025?

SOBEN Pharma Robeerst recorded a loss after taxes of € 95,016 in financial year 2025.

What is the revenue of SOBEN Pharma Robeerst?

As a small company, SOBEN Pharma Robeerst is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -44,046.

How much does an employee at SOBEN Pharma Robeerst earn?

The average wage cost per full-time employee at SOBEN Pharma Robeerst was € 75,500 in 2024: staff costs of € 98,204 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does SOBEN Pharma Robeerst have?

According to the 2025 annual accounts, SOBEN Pharma Robeerst has 0.7 full-time equivalents (FTE).

SOBEN Pharma Robeerst (Private Limited) - Esneux

Dossier SOBEN Pharma Robeerst, printed on 30 October 2026 from databakkes.be/en/0416405162/soben-pharma-robeerst. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 1.6 to 0.7.

Financials

Financial year 2025

SOBEN Pharma Robeerst from Esneux, company number BE0416405162, closed financial year 2025 with a result of € -95,016 after tax. For that financial year SOBEN Pharma Robeerst recorded a gross margin of € -44,046 and equity of € 22,241. Compared with financial year 2024, the result moved from € 28,116 to € -95,016. The company made a loss. The buffer shrank hard: equity is 81 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 4, 2026.

What it is worth Shrank hard

€ 22,241

▼ 81% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -95,016

▼ still € 28,116 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,348

▼ 44% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 3,491.

People and assets in 2025

Full-time equivalents

0.7

▼ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 27,739

▼ 72% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 48,838

▼ 15% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 259,573

▼ 34% vs 2024

€ 27,121 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 1,139

▼ 99% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 240,666 Gross margin 2022: € 240,666 First fiscal year in the series	€ 129,584 Gross margin 2023: € 129,584 ▼ 46% vs 2022 (€ 240,666) Unfavourable step	€ 189,470 Gross margin 2024: € 189,470 ▲ 46% vs 2023 (€ 129,584) Favourable step	€ -44,046 Gross margin 2025: € -44,046 ▼ € 233,517 vs 2024 (€ 189,470) Unfavourable step	▼ € 233,517
Profit after taxes	€ 115,992 Profit after taxes 2022: € 115,992 First fiscal year in the series	€ -23,310 Profit after taxes 2023: € -23,310 ▼ € 139,302 vs 2022 (€ 115,992) Unfavourable step	€ 28,116 Profit after taxes 2024: € 28,116 ▲ € 51,426 vs 2023 (€ -23,310) Favourable step	€ -95,016 Profit after taxes 2025: € -95,016 ▼ € 123,132 vs 2024 (€ 28,116) Unfavourable step	▼ € 123,132
Equity	€ 147,452 Equity 2022: € 147,452 First fiscal year in the series	€ 124,141 Equity 2023: € 124,141 ▼ 16% vs 2022 (€ 147,452) Unfavourable step	€ 117,257 Equity 2024: € 117,257 ▼ 6% vs 2023 (€ 124,141) Unfavourable step	€ 22,241 Equity 2025: € 22,241 ▼ 81% vs 2024 (€ 117,257) Unfavourable step	▼ 81%
Total debts	€ 773,407 Total debts 2022: € 773,407 First fiscal year in the series	€ 691,423 Total debts 2023: € 691,423 ▼ 11% vs 2022 (€ 773,407) Favourable step	€ 731,903 Total debts 2024: € 731,903 ▲ 6% vs 2023 (€ 691,423) Unfavourable step	€ 260,712 Total debts 2025: € 260,712 ▼ 64% vs 2024 (€ 731,903) Favourable step	▼ 64%
Cash	€ 6,810 Cash 2022: € 6,810 First fiscal year in the series	€ 11,663 Cash 2023: € 11,663 ▲ 71% vs 2022 (€ 6,810) Favourable step	€ 7,830 Cash 2024: € 7,830 ▼ 33% vs 2023 (€ 11,663) Unfavourable step	€ 4,348 Cash 2025: € 4,348 ▼ 44% vs 2024 (€ 7,830) Unfavourable step	▼ 44%
Retained profit	€ 128,702 Retained profit 2022: € 128,702 First fiscal year in the series	€ 105,391 Retained profit 2023: € 105,391 ▼ 18% vs 2022 (€ 128,702) Unfavourable step	€ 98,507 Retained profit 2024: € 98,507 ▼ 7% vs 2023 (€ 105,391) Unfavourable step	€ 3,491 Retained profit 2025: € 3,491 ▼ 96% vs 2024 (€ 98,507) Unfavourable step	▼ 96%
Dividend	€ 125,000 Dividend 2022: € 125,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 125,000) Unchanged	€ 35,000 Dividend 2024: € 35,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 35,000) Unchanged	▼ 100%
Bank debt	€ 236,945 Bank debt 2022: € 236,945 First fiscal year in the series	€ 197,468 Bank debt 2023: € 197,468 ▼ 17% vs 2022 (€ 236,945) Favourable step	€ 394,256 Bank debt 2024: € 394,256 ▲ 100% vs 2023 (€ 197,468) Unfavourable step	€ 259,573 Bank debt 2025: € 259,573 ▼ 34% vs 2024 (€ 394,256) Favourable step	▼ 34%
Balance sheet total	€ 952,455 Balance sheet total 2022: € 952,455 First fiscal year in the series	€ 843,834 Balance sheet total 2023: € 843,834 ▼ 11% vs 2022 (€ 952,455) Unchanged	€ 874,102 Balance sheet total 2024: € 874,102 ▲ 4% vs 2023 (€ 843,834) Unchanged	€ 282,954 Balance sheet total 2025: € 282,954 ▼ 68% vs 2024 (€ 874,102) Unchanged	▼ 68%
Employees (FTE)	1.3 Employees (FTE) 2022: 1.3 First fiscal year in the series	1.6 Employees (FTE) 2023: 1.6 ▲ 0.3 vs 2022 (1.3) Unchanged	1.3 Employees (FTE) 2024: 1.3 ▼ 0.3 vs 2023 (1.6) Unchanged	0.7 Employees (FTE) 2025: 0.7 ▼ 0.6 vs 2024 (1.3) Unchanged	▼ 0.6

Key figures of SOBEN Pharma Robeerst, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SOBEN Pharma Robeerst?

What happened at SOBEN Pharma Robeerst in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 4, 2026 New annual accounts for financial year 2025: loss of € 95,016 (▼ € 123,132 vs 2024). Source: NBB ↗
2007 Alphar Esneux SA became a director. NBB
Oct 1, 1976 New establishment in Esneux. KBO
Sep 20, 1976 Start of the company according to the CBE. KBO

In short

From € 115,992 profit in 2022 to € 95,016 loss in 2025.

Paid € 34,250 in corporate taxes since 2022.

Best year ever: 2022, with € 115,992 profit.

On average € 145,700 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

ALPHAR ESNEUX 99.9%

The stake of ALPHAR ESNEUX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

SOBEN Pharma Robeerst

Behind SOBEN Pharma Robeerst is Alphar Esneux SA. The shares are held by ALPHAR ESNEUX (99.9%).

Directors

According to the 2025 annual accounts

Alphar Esneux SA

Director · represented by Robeerst Séverine

Also active at: SOBEN Pharma Station

since 2007

Shareholders

ALPHAR ESNEUX

99.9%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Bruxelles 17

4130 Esneux

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

UNITE TVA DU GROUPE ROBEERST

Association des copropriétaires de la "Résidence RIVE GAUCHE" à Esneux, rue de Bruxelles, 17.

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0416.405.162

VAT number

BE 0416.405.162

Registered office

Rue de Bruxelles 17, 4130 Esneux

Names & denominations

SOBEN Pharma Robeerst

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

20 September 1976

Peppol

Active · Active since 16 Jul 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

SOBEN Pharma Robeerst

Warning lights

Financials

What happened to SOBEN Pharma Robeerst?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions